Ultragenyx prices gene therapy at $3.95 million

Ultragenyx has priced its newly approved gene therapy Fayuvi at $3.95 million for Sanfilippo syndrome Type A. The one-time treatment aims to halt cognitive and motor decline in pediatric patients.

Xurve View
Insights:
FILE PHOTO: Signage is seen outside of the Food and Drug Administration headquarters in White Oak, Maryland, U.S., August 29, 2020.

ULTRAGENYX PHARMACEUTICAL IN set a list price of $3.95 million for its newly approved gene therapy Fayuvi, launching a record-setting one-time treatment for a fatal childhood condition. The therapy addresses Sanfilippo syndrome Type A, an inherited illness that progressively destroys brain and nervous tissue in pediatric patients. The rollout arrives as families face lifetime care costs exceeding $8 million per patient.